Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.41 -0.14 (-0.49%)
Streaming Delayed Price Updated: 3:01 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
The company is still looking to bounce back after the beating it took in recent years. 
Via The Motley Fool
Topics Economy
News headline image
1 Stock Under $50 to Target This Week and 2 That Underwhelm
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
IP Group H1 Earnings Call Highlights ↗
IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio... 
Via MarketBeat
Topics Earnings Initial Public Offering
News headline image
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗
Analysts think Alnylam could rebound strongly over the next 12 months. 
Via The Motley Fool
News headline image
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗
Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining... 
Via MarketBeat
Topics Intellectual Property World Trade
News headline image
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
How Concerned Should Income Investors Be About Pfizer's Dividend? ↗
Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo... 
Via MarketBeat
Topics ETFs
News headline image
1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges
Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo... 
Via StockStory
News headline image
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot ↗
Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with... 
Via MarketBeat
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
News headline image
This Is What I'd Do With Pfizer Stock Right Now ↗
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Things You Need to Know If You Buy Pfizer Stock Today ↗
After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion ↗
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties. 
Via Benzinga
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
Wednesday's session: most active stock in the S&P500 index ↗
Via Chartmill
News headline image
Should You Buy Pfizer Stock Below $30? ↗
Patient investors who buy the stock may be rewarded over the long term. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector. 
Via The Motley Fool
News headline image
Top Companies Using Salesforce CRM in the USA ↗
Salesforce powers the engine behind America’s most ambitious brands. From retail giants to global banks, its footprint is massive. Therefore, marketers eve 
Via Talk Markets
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.